Free Trial
Your Portfolio Deserves Better! MarketBeat All Access for Just $149
Upgrade Now
Claim MarketBeat All Access Sale Promotion

Prothena (PRTA) Competitors

Prothena logo
$9.59 -0.17 (-1.74%)
Closing price 05/18/2026 04:00 PM Eastern
Extended Trading
$9.85 +0.26 (+2.66%)
As of 05/18/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PRTA vs. ADPT, NBTX, BHC, OCUL, and ZLAB

Should you buy Prothena stock or one of its competitors? MarketBeat compares Prothena with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Prothena include Adaptive Biotechnologies (ADPT), Nanobiotix (NBTX), Bausch Health Cos (BHC), Ocular Therapeutix (OCUL), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry.

How does Prothena compare to Adaptive Biotechnologies?

Prothena (NASDAQ:PRTA) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

Prothena has a beta of -0.23, indicating that its share price is 123% less volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.16, indicating that its share price is 116% more volatile than the broader market.

Adaptive Biotechnologies has higher revenue and earnings than Prothena. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prothena$9.68M51.86-$244.09M-$2.82N/A
Adaptive Biotechnologies$276.98M7.34-$59.50M-$0.33N/A

In the previous week, Prothena had 6 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 12 mentions for Prothena and 6 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 0.41 beat Prothena's score of -0.47 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Prothena
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Adaptive Biotechnologies
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Prothena currently has a consensus price target of $21.78, suggesting a potential upside of 127.09%. Adaptive Biotechnologies has a consensus price target of $19.57, suggesting a potential upside of 53.98%. Given Prothena's higher possible upside, equities analysts clearly believe Prothena is more favorable than Adaptive Biotechnologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prothena
2 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.36
Adaptive Biotechnologies
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

97.1% of Prothena shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 10.4% of Prothena shares are held by insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Adaptive Biotechnologies has a net margin of -16.82% compared to Prothena's net margin of -260.92%. Adaptive Biotechnologies' return on equity of -40.06% beat Prothena's return on equity.

Company Net Margins Return on Equity Return on Assets
Prothena-260.92% -43.44% -36.87%
Adaptive Biotechnologies -16.82%-40.06%-16.64%

Summary

Adaptive Biotechnologies beats Prothena on 11 of the 17 factors compared between the two stocks.

How does Prothena compare to Nanobiotix?

Nanobiotix (NASDAQ:NBTX) and Prothena (NASDAQ:PRTA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

Nanobiotix currently has a consensus target price of $26.67, suggesting a potential downside of 46.11%. Prothena has a consensus target price of $21.78, suggesting a potential upside of 127.09%. Given Prothena's higher probable upside, analysts plainly believe Prothena is more favorable than Nanobiotix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nanobiotix
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Prothena
2 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.36

38.8% of Nanobiotix shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by insiders. Comparatively, 10.4% of Prothena shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Nanobiotix has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Nanobiotix's return on equity of 0.00% beat Prothena's return on equity.

Company Net Margins Return on Equity Return on Assets
NanobiotixN/A N/A N/A
Prothena -260.92%-43.44%-36.87%

Nanobiotix has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market. Comparatively, Prothena has a beta of -0.23, indicating that its stock price is 123% less volatile than the broader market.

Nanobiotix has higher revenue and earnings than Prothena.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nanobiotix$36.87M65.11-$27.11MN/AN/A
Prothena$9.68M51.86-$244.09M-$2.82N/A

In the previous week, Prothena had 11 more articles in the media than Nanobiotix. MarketBeat recorded 12 mentions for Prothena and 1 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.42 beat Prothena's score of -0.47 indicating that Nanobiotix is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nanobiotix
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Prothena
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Nanobiotix beats Prothena on 9 of the 14 factors compared between the two stocks.

How does Prothena compare to Bausch Health Cos?

Prothena (NASDAQ:PRTA) and Bausch Health Cos (NYSE:BHC) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

97.1% of Prothena shares are owned by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are owned by institutional investors. 10.4% of Prothena shares are owned by insiders. Comparatively, 20.7% of Bausch Health Cos shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Prothena had 5 more articles in the media than Bausch Health Cos. MarketBeat recorded 12 mentions for Prothena and 7 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 0.00 beat Prothena's score of -0.47 indicating that Bausch Health Cos is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Prothena
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Bausch Health Cos
0 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Prothena currently has a consensus price target of $21.78, indicating a potential upside of 127.09%. Bausch Health Cos has a consensus price target of $8.00, indicating a potential upside of 49.39%. Given Prothena's stronger consensus rating and higher possible upside, analysts clearly believe Prothena is more favorable than Bausch Health Cos.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prothena
2 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.36
Bausch Health Cos
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80

Bausch Health Cos has higher revenue and earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prothena$9.68M51.86-$244.09M-$2.82N/A
Bausch Health Cos$10.27B0.19$157M-$3.24N/A

Prothena has a beta of -0.23, meaning that its share price is 123% less volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

Bausch Health Cos has a net margin of -11.47% compared to Prothena's net margin of -260.92%. Prothena's return on equity of -43.44% beat Bausch Health Cos' return on equity.

Company Net Margins Return on Equity Return on Assets
Prothena-260.92% -43.44% -36.87%
Bausch Health Cos -11.47%-2,922.77%5.63%

Summary

Prothena beats Bausch Health Cos on 9 of the 17 factors compared between the two stocks.

How does Prothena compare to Ocular Therapeutix?

Ocular Therapeutix (NASDAQ:OCUL) and Prothena (NASDAQ:PRTA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

In the previous week, Prothena had 8 more articles in the media than Ocular Therapeutix. MarketBeat recorded 12 mentions for Prothena and 4 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.49 beat Prothena's score of -0.47 indicating that Ocular Therapeutix is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ocular Therapeutix
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Prothena
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Ocular Therapeutix currently has a consensus target price of $23.78, suggesting a potential upside of 183.74%. Prothena has a consensus target price of $21.78, suggesting a potential upside of 127.09%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, research analysts clearly believe Ocular Therapeutix is more favorable than Prothena.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocular Therapeutix
1 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.79
Prothena
2 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.36

Prothena has lower revenue, but higher earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocular Therapeutix$51.95M35.32-$265.94M-$1.46N/A
Prothena$9.68M51.86-$244.09M-$2.82N/A

59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 2.3% of Ocular Therapeutix shares are owned by insiders. Comparatively, 10.4% of Prothena shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Prothena has a net margin of -260.92% compared to Ocular Therapeutix's net margin of -558.24%. Prothena's return on equity of -43.44% beat Ocular Therapeutix's return on equity.

Company Net Margins Return on Equity Return on Assets
Ocular Therapeutix-558.24% -64.28% -48.15%
Prothena -260.92%-43.44%-36.87%

Ocular Therapeutix has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Prothena has a beta of -0.23, suggesting that its stock price is 123% less volatile than the broader market.

Summary

Prothena beats Ocular Therapeutix on 10 of the 17 factors compared between the two stocks.

How does Prothena compare to Zai Lab?

Zai Lab (NASDAQ:ZLAB) and Prothena (NASDAQ:PRTA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Zai Lab has a net margin of -39.29% compared to Prothena's net margin of -260.92%. Zai Lab's return on equity of -24.32% beat Prothena's return on equity.

Company Net Margins Return on Equity Return on Assets
Zai Lab-39.29% -24.32% -15.52%
Prothena -260.92%-43.44%-36.87%

In the previous week, Prothena had 7 more articles in the media than Zai Lab. MarketBeat recorded 12 mentions for Prothena and 5 mentions for Zai Lab. Zai Lab's average media sentiment score of 0.18 beat Prothena's score of -0.47 indicating that Zai Lab is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zai Lab
1 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Prothena
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Zai Lab presently has a consensus price target of $45.83, indicating a potential upside of 143.02%. Prothena has a consensus price target of $21.78, indicating a potential upside of 127.09%. Given Zai Lab's stronger consensus rating and higher probable upside, research analysts clearly believe Zai Lab is more favorable than Prothena.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zai Lab
2 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.63
Prothena
2 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.36

Zai Lab has higher revenue and earnings than Prothena. Zai Lab is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zai Lab$460.16M4.65-$175.54M-$1.62N/A
Prothena$9.68M51.86-$244.09M-$2.82N/A

Zai Lab has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market. Comparatively, Prothena has a beta of -0.23, indicating that its stock price is 123% less volatile than the broader market.

41.7% of Zai Lab shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 4.9% of Zai Lab shares are owned by company insiders. Comparatively, 10.4% of Prothena shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Zai Lab beats Prothena on 11 of the 16 factors compared between the two stocks.

Get Prothena News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PRTA vs. The Competition

MetricProthenaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$510.97M$3.31B$6.25B$12.29B
Dividend YieldN/A2.34%2.80%5.30%
P/E Ratio-3.4018.1320.8625.23
Price / Sales51.86275.96550.9175.54
Price / CashN/A55.2727.4837.30
Price / Book1.846.579.676.63
Net Income-$244.09M$24.35M$3.56B$335.59M
7 Day Performance1.70%-2.53%-1.69%-1.20%
1 Month Performance-12.02%-3.55%-2.65%-1.16%
1 Year Performance29.59%53.51%30.03%28.10%

Prothena Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRTA
Prothena
1.9283 of 5 stars
$9.59
-1.7%
$21.78
+127.1%
+33.6%$510.97M$9.68MN/A130
ADPT
Adaptive Biotechnologies
3.5255 of 5 stars
$13.54
-2.0%
$20.00
+47.7%
+40.4%$2.21B$276.98MN/A790
NBTX
Nanobiotix
1.4287 of 5 stars
$53.55
+17.7%
$26.67
-50.2%
+1,173.6%$2.21B$36.87MN/A100
BHC
Bausch Health Cos
2.064 of 5 stars
$5.36
-6.9%
$8.00
+49.4%
+14.5%$2.15B$10.27BN/A20,300
OCUL
Ocular Therapeutix
3.5364 of 5 stars
$9.28
-3.8%
$23.78
+156.2%
+16.1%$2.11B$51.95MN/A230

Related Companies and Tools


This page (NASDAQ:PRTA) was last updated on 5/19/2026 by MarketBeat.com Staff.
From Our Partners